COVID-19 is an infectious disease caused by the SARS-CoV-2 virus, which rapidly spread worldwide and resulted in a pandemic. Efficient and sensitive detection techniques have been devised since the…
New contract value of up to £617,000 Contract value visibility for the current financial year of £1.75 million 04 Nov, 2025: Aptamer Group plc (AIM: APTA), the developer of next-generation…
Using multiple discovery methods in aptamer development provides better binders. Learn why multiple discovery methods are important, which is right for you and how they can be combined for…
Cancer remains a mammoth challenge, accounting for one in every six deaths globally. But aptamers are offering new solutions from reagents to next-gen ADCs. Despite the scale of the…
In this webinar Aptamer’s Chief Scientific Officer, Dr David Bunka, discusses how Optimers can be used for developing cancer research reagents, new therapies and diagnostic tools. Aptamers, initially discovered…
April 25th is DNA Day and we’re celebrating DNA aptamers and the innovation they are bringing from new medicines to new life science reagents. This day was set up…
Optimer-Fc integrates the benefits of Optimer binders with the Fc portion of an antibody to enhance the target range and selectivity of immunohistochemistry (IHC) reagent to advance analysis of…
Optimer® are novel reagents for use in IHC applications to localise new biomarkers and improve accuracy for current biomarkers, in both FFPE and frozen tissues. Download this application note to…
When selecting the right IHC reagent make sure you consider these three factors and find out how IHC aptamers can help ensure success from the start. Immunohistochemistry, IHC for short,…
Reversible binding is essential for affinity chromatography. We discuss how to ensure you meet this critical property when developing aptamers for aptamer-based affinity chromatography applications. In developing affinity chromatography…
